(NASDAQ: INAB) In8bio's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 5.22%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 14.9%.
In8bio's earnings in 2025 is -$23,890,000.On average, 1 Wall Street analyst forecast INAB's earnings for 2025 to be -$25,921,784, with the lowest INAB earnings forecast at -$25,921,784, and the highest INAB earnings forecast at -$25,921,784. On average, 2 Wall Street analysts forecast INAB's earnings for 2026 to be -$25,240,827, with the lowest INAB earnings forecast at -$25,921,784, and the highest INAB earnings forecast at -$24,559,869.
In 2028, INAB is forecast to generate $73,550,679 in earnings, with the lowest earnings forecast at $73,550,679 and the highest earnings forecast at $73,550,679.